

1 **Title**

2 A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-
3 2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with
4 centralized assays across healthcare facilities in the United States

5

6 **Authors**

7 Elissa M. Robbins^{a#}

8 Rasa Bertuzis^a

9 Ho-Chen Chiu^b

10 Lupe Miller^a

11 Christopher Noutsios^a

12

13 **Affiliations**

14 ^aRoche Molecular Systems, Inc., Pleasanton, California, USA

15 ^bRoche Sequencing Solutions, Inc., Indianapolis, Indiana, USA

16

17 **#Corresponding author**

18 Elissa M. Robbins

19

20 **Running title**

21 Cobas Liat SARS-CoV-2 & Influenza A/B test

22 **Non-structured abstract**

23 Respiratory diseases can share many of the same symptoms, highlighting the need for
24 timely and accurate differentiation to facilitate effective clinical management and reduce
25 transmission. Compared with centralized testing, molecular point-of-care tests (POCT) can
26 provide a faster time to result.

27 We evaluated the RT-PCR POCT Cobas[®] SARS-CoV-2 & Influenza A/B qualitative assay for
28 use on the Cobas Liat[®] system (the Cobas Liat SARS-CoV-2 & Influenza A/B test) in nasal
29 and nasopharyngeal swab samples from 10 diverse healthcare facilities in the US. A
30 composite comparator design consisting of three centralized tests was used to analyze
31 SARS-CoV-2, whilst performance versus a single centralized test was used for analysis of
32 influenza A and B. Evaluations included performance stratified by sample type
33 (prospective/retrospective and nasal/nasopharyngeal [paired by subject]), collection method
34 (self/healthcare worker-collected [alternated and approximately balanced], symptom status
35 (symptomatic/asymptomatic), and SARS-CoV-2 vaccination status, as well as assay
36 inclusivity and system ease of use.

37 A total of 2,247 samples were tested. For SARS-CoV-2, the overall percent agreement (OPA)
38 was 98.8% (95% CI: 97.9, 99.3) in nasal swab samples and 99.0% (95% CI: 98.2, 99.4) in
39 nasopharyngeal swab samples. Regression analysis showed that Ct values from paired nasal
40 and nasopharyngeal swab samples were highly correlated (correlation coefficient 0.83). The
41 OPA was $\geq 99.5\%$ (sample type dependent) and 100.0% for influenza A and B, respectively.
42 The Cobas Liat SARS-CoV-2 & Influenza A/B test was easy to use.

43 These results support the use of the POCT in various sample types and by various operators
44 in the intended-use setting.

45 **Summary statement/importance**

46 This study highlights the benefits of RT-PCR POCT, namely comparable performance to
47 centralized testing in multiple sample types and ease of use. Utilizing assays such as the
48 Cobas Liat SARS-CoV-2 & Influenza A/B test may improve timely differentiation of
49 respiratory diseases that share similar symptoms.

50 **Introduction**

51 More than 4 years since the start of the coronavirus disease 2019 (COVID-19) pandemic,
52 much of the world has returned to normality, yet COVID-19 continues to cause severe illness
53 and mortality in the United States (US) and elsewhere(1, 2). This applies particularly for the
54 immunocompromised, who are at risk of severe outcomes (3) and comprise approximately
55 3% of the US adult population(4). Disease activity is year-round, but seasonal spikes occur
56 from November to April(5), coinciding with circulation of other respiratory viruses, such as
57 influenza(6). Respiratory diseases such as COVID-19 and influenza share similar
58 symptoms(7), highlighting the need for timely and accurate differentiation of the causative
59 agent to help facilitate effective clinical management and reduce onward transmission.

60 The current choice of testing for severe acute respiratory syndrome coronavirus 2 (SARS-
61 CoV-2) is setting dependent(8), but standard laboratory-based (i.e., centralized) nucleic acid
62 amplification tests are the mainstay of diagnosis(9). Numerous antigen or molecular point-
63 of-care tests (POCT) are commercially available(10, 11), offering the benefit of a faster time
64 to result(12). Both POCT formats have lower performance compared with centralized
65 testing, particularly sensitivity (13) — a secondary analysis of antigen POCT found the
66 performance to be commonly lower than stated within manufacturers' instructions for use
67 (14) — but molecular POCT have relatively higher performance in comparison with antigen
68 POCT, with pooled sensitivity values of 93% (99% specificity) versus 71% (99% specificity),
69 respectively(13). Molecular POCT can provide actionable results in as little as 20 minutes
70 depending on the assay and workflow(11).

71 Influenza is a significant cause of severe illness and death(15-17), resulting in a substantial
72 clinical burden to patients and the healthcare system alike(18). Molecular POCT for the
73 detection of influenza A/B subtypes, and other respiratory viruses such as respiratory
74 syncytial virus, have been available for several years(11, 12, 19-22). Clinical practice
75 guidelines from the Infectious Diseases Society of America recommend that antivirals are
76 initiated for certain patient groups as soon as possible regardless of illness duration, or
77 within 48 hours of illness onset(23), supporting the use of rapid molecular POCT for
78 influenza testing in preference to centralized laboratory testing. In the hospital setting, an
79 interventional study of a molecular POCT for influenza found significant improvements in
80 isolation practices and reductions in length of stay compared with centralized testing(24),
81 whilst a modeling study found that the introduction of POCT could reduce time to diagnosis,
82 hospital stay, and in-hospital costs(25). Molecular POCT for influenza can generate sensitivity
83 estimates of ≥ 96 –100% in real-world settings(22, 26).

84 The primary objective of this study was to evaluate the real-world clinical performance of
85 the POC Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat
86 system (herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test), a
87 multiplexed RT-PCR test combining measurement of SARS-CoV-2 and influenza subtypes, in
88 reference to comparator centralized PCR tests for SARS-CoV-2 and influenza A and B viruses.
89 Sample types were nasal and nasopharyngeal swab specimens from individuals suspected of
90 respiratory viral infection consistent with COVID-19, and asymptomatic individuals exposed
91 to COVID-19, who presented at healthcare facilities across the US during the COVID-19
92 public health emergency. Secondary objectives were to evaluate the influence of collection
93 method and the ease of use of the Cobas Liat system.

94 **Materials and methods**

95 **Sites**

96 Testing was conducted at 11 sites: 10 geographically diverse healthcare facilities that were
97 representative of intended-use sites (i.e., POC settings, such as emergency departments,
98 urgent care, pediatric and primary care clinics, and drive-through COVID-19 testing sites),
99 and one reference laboratory for centralized testing. After testing using the Cobas Liat SARS-
100 CoV-2 & Influenza A/B test at the healthcare facilities, samples were shipped to the
101 reference laboratory for analysis with the comparator assays (see below).

102 Healthcare facilities were selected based on sample availability, ability to provide adequate
103 resources and operators, ability to adhere to good clinical practice, and with the aim of
104 ensuring representation of the demographic diversity of the US population. Not all
105 healthcare facilities performing testing were certified under Clinical Laboratory Improvement
106 Amendments (CLIA) regulations to perform waived testing, but all facilities met the
107 requirements for CLIA-waived settings (i.e., intended-use settings using untrained non-
108 laboratory personnel). All healthcare facilities performed both sample collection and POC
109 testing. POC operators at the 10 healthcare facilities (n=30 operators in total) had limited or
110 no laboratory training and were representative of typical test operators in CLIA-waived
111 settings (e.g., nurses, nursing assistants, and medical assistants). Operators at the reference
112 laboratory were blinded to the results generated at the healthcare facilities.

113 **Study population**

114 The symptomatic group comprised samples from individuals with suspected respiratory viral
115 infection consistent with COVID-19 (see Signs/symptoms, Supplementary material). The
116 asymptomatic group comprised individuals with self-reported 'recent' exposure (timeframe
117 undefined) to SARS-CoV-2-positive individuals or any other reasons to suspect COVID-19.
118 Patient clinical information was gathered, including, but not limited to, antiviral usage for up

119 to 7 days prior to and on the day of sample collection, gender, race/ethnic group, and age.
120 Individuals presenting at the healthcare facilities were considered for study inclusion, subject
121 to the eligibility criteria (see Eligibility criteria, Supplementary material).

122 **Study design**

123 The clinical performance of the POC Cobas Liat SARS-CoV-2 & Influenza A/B test (27) was
124 evaluated by comparing results to a composite comparator method for the SARS-CoV-2
125 analyte using the following three highly sensitive centralized testing assays: Cobas SARS-
126 CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the
127 Cobas 6800/8800 SARS-CoV-2 test)(28); Cobas SARS-CoV-2 & Influenza A/B qualitative
128 assay for use on the Cobas 6800/8800 systems (herein referred to as the Cobas 6800/8800
129 SARS-CoV-2 & Influenza A/B test)(29); and Hologic[®] Aptima[®] SARS-CoV-2 Assay(30).

130 The clinical performance for the influenza A/B analyte components of the Cobas Liat SARS-
131 CoV-2 & Influenza A/B test was evaluated against a single centralized testing assay, the
132 Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test(29).

133 Samples that generated invalid results were repeated where sample volume permitted
134 additional testing; samples generating a second invalid result upon retesting were reported
135 as invalid. Interrogation of discrepant samples was not performed, though selected samples
136 were further retested with the Cobas Liat SARS-CoV-2 & Influenza A/B test for exploratory
137 purposes.

138 **Sample types and collection**

139 Sample types included fresh and frozen nasal and nasopharyngeal swab samples, collected
140 in the same media formulations but under different brand names: Copan Universal Transport
141 Medium (UTM) or BD Universal Viral Transport (UVT) medium.

142 Prospective fresh samples (UTM)

143 One nasal swab and one nasopharyngeal swab sample were collected from each study
144 participant. A nasal swab of both nostrils was first collected either by the healthcare worker
145 (HCW), herein referred to as 'HCW-collected', or by the study participant under instruction
146 from the HCW, herein referred to as 'self-collected', as per manufacturer's instructions.(31) A
147 nasopharyngeal swab was then collected by HCWs from the same study participant to
148 generate paired samples. If a nasopharyngeal swab had already been collected (using one
149 nostril) as part of the healthcare facility's standard of care, the study nasopharyngeal swab
150 was taken from the opposite nostril.

151 All prospective samples were collected from patients presenting to healthcare facilities
152 during February to June 2022, characteristic of the 2021/2022 winter respiratory season.

153 Retrospective frozen samples (archived or purchased from external vendors; UTM or UVT)

154 The low influenza prevalence in the prospective population was anticipated because of
155 reduced international travel, new respiratory care paradigms, increased public health
156 awareness, and use of interventions (such as masking policies or social distancing) that
157 occurred during the COVID-19 pandemic and study enrollment period, in which influenza A
158 virus had been the dominant virus type in circulation.(32) Therefore, frozen samples positive
159 for influenza A virus and for influenza B virus were used to supplement the prospectively
160 collected fresh samples. These retrospective samples were collected in the US during the
161 2013–2014, 2014–2015, and 2019–2020 influenza seasons. Baseline demographic data and
162 patient characteristics related to these samples were unavailable.

163 Retrospective samples with known SARS-CoV-2 status, collected between March 29, 2021
164 and May 26, 2021, were also included in the SARS-CoV-2 analyses.

165 Whilst multiple freeze-thaw cycles have a limited effect on the viral titer(33), there is the
166 potential for samples that were initially low-titer positives to appear negative following
167 storage. Internal Roche data support the stability of viral titer for up to three freeze-thaw
168 cycles, so retrospective samples were only eligible for inclusion if they had undergone no
169 more than two freeze-thaw cycles. Retrospective positive and negative samples were
170 blended in a standard POCT workflow and assessed alongside prospectively collected
171 samples.

172 **Details of assays and instruments**

173 Cobas Liat SARS-CoV-2 & Influenza A/B test (POC RT-PCR)

174 The Cobas Liat analyzer is for *in vitro* diagnostic use(27). The analyzer automates all nucleic
175 acid amplification test processes, including target enrichment, inhibitor removal, nucleic acid
176 extraction, reverse transcription, DNA amplification, real-time detection, and result
177 interpretation in approximately 20 minutes(27). The Cobas Liat system comprises the Cobas
178 Liat analyzer in conjunction with the Cobas Liat assay tubes(27).

179 The Cobas Liat SARS-CoV-2 & Influenza A/B test utilizes a single-use disposable assay tube
180 that contains all the reagents necessary for the detection of SARS-CoV-2 and hosts the
181 sample preparation and PCR processes(34). This multiplex real-time RT-PCR test is intended
182 for the simultaneous rapid *in vitro* qualitative detection and differentiation of SARS-CoV-2,
183 influenza A, and influenza B virus RNA in healthcare provider-collected nasal and
184 nasopharyngeal swab samples and self-collected nasal swab samples (collected in a
185 healthcare setting with instruction by a healthcare provider) from individuals suspected of
186 respiratory viral infection consistent with COVID-19(34).

187 Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test (centralized testing method [CTM] 1)

188 The Cobas 6800/8800 systems consists of the sample supply module, the transfer module,
189 the processing module, and the analytic module(29). Automated data management is
190 performed by the Cobas 6800/8800 software, which assigns results for all tests. Results are
191 available within less than 3.5 hours after loading the sample on the system.(29) The positive
192 SARS-CoV-2 result is defined as positive on the SARS-CoV-2 channel (Target 2) and/or the
193 pan-sarbeco channel (Target 3).

194 The Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test is an automated multiplex real-time
195 RT-PCR assay intended for simultaneous qualitative detection and differentiation of SARS-
196 CoV-2, influenza A virus, and/or influenza B virus RNA in healthcare provider-collected nasal
197 and nasopharyngeal swab samples and self-collected nasal swab samples (collected in a
198 healthcare setting with instruction by a healthcare provider) from individuals suspected of
199 respiratory viral infection consistent with COVID-19(29).

200 Cobas 6800/8800 SARS-CoV-2 test (CTM 2)

201 The Cobas 6800/8800 SARS-CoV-2 test is an automated real-time RT-PCR assay intended for
202 the qualitative detection of nucleic acids from SARS-CoV-2 in healthcare provider-instructed,
203 self-collected anterior nasal (nasal) swab samples (collected onsite) and healthcare provider-
204 collected nasal, nasopharyngeal, and oropharyngeal swab samples collected from any
205 individuals, including those suspected of COVID-19 by their healthcare provider, and those
206 without symptoms or with other reasons to suspect COVID-19(28). The positive SARS-CoV-2
207 result is defined as positive on the SARS-CoV-2 channel (Target 1) and/or the pan-sarbeco
208 channel (Target 2).

209 Hologic Aptima SARS-CoV-2 assay (tiebreaker; CTM 3)

210 As a commonly used molecular assay(30), CTM 3 was utilized as a tiebreaker. The test
211 utilizes transcription-mediated amplification for the qualitative detection of RNA from SARS-
212 CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal
213 swab samples, nasopharyngeal wash/aspirate, or nasal aspirates obtained from individuals
214 meeting COVID-19 clinical and/or epidemiological criteria(35).

215 **Analyses**

216 All data analyses were performed using SAS/STAT[®] software (v9.4 or higher of the SAS
217 System for Linux). No formal sample size calculations were calculated for this study, but
218 patient enrollment was adjusted to accommodate disease prevalence and to generate a
219 minimum of 50 SARS-CoV-2 positives, 30 influenza A positives, and 10 influenza B positives
220 for analysis.

221 The clinical performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test was evaluated
222 using estimates of positive percent agreement (PPA), negative percent agreement (NPA),
223 and overall percent agreement (OPA), calculated with 2-sided 95% confidence intervals (CI)
224 using the Wilson-score method(36). Comparison was against either the composite
225 comparator for SARS-CoV-2 (CTM 1, CTM 2, and CTM 3 [tiebreaker if required]) or a single
226 comparator for influenza A/B (CTM 1).

227 For SARS-CoV-2, concordant results from CTM 1 and CTM 2 established true positive or true
228 negative status. In the event of discordance between CTM 1 and CTM 2, CTM 3 (the
229 tiebreaker) was used to establish true status. Samples could be coded as uninterpretable in
230 the event of invalid, failed, aborted or missing results that were not resolved upon retesting.
231 If CTM 1 or CTM 2 or CTM 3 returned uninterpretable results, and the other two methods
232 returned different results (i.e., CTM 1 positive, CTM 2 negative, and CTM 3 uninterpretable),
233 then the status of the sample would be described as indeterminate.

234 McNemar's mid-p test (P-value) was used to assess any differences between sample types. A
235 P-value of <0.05 was considered statistically significant.

236 POCT operators were asked to complete a questionnaire to evaluate the ease of use of the
237 Cobas Liat SARS-CoV-2 & Influenza A/B test.

238 *In silico* analysis of the Cobas Liat SARS-CoV-2 & Influenza A/B test was performed to assess
239 assay design inclusivity on all available SARS-CoV-2 sequences (taxonomy ID 2697049) in
240 the Global Initiative on Sharing All Influenza Data (GISAID) and National Center for
241 Biotechnology Information (NCBI) databases up to July 2024 (>16,800,000 sequences in
242 NCBI and >8,900,000 sequences in GISAID). The predicted impact of each variant on gene
243 target 1 and gene target 2 primer and probe binding site sequence was evaluated using
244 Roche proprietary software and Melting5 software. A SARS-CoV-2 sequence would be
245 potentially not detected by the Cobas Liat SARS-CoV-2 & Influenza A/B test if a delay in
246 cycle threshold greater than five cycles and/or a probe melting temperature of <65°C was
247 predicted.

248 **Ethics statement**

249 This study was a non-interventional evaluation of an *in vitro* diagnostic device (test results
250 were not used to inform patient care decisions). This study was conducted in compliance
251 with International Conference on Harmonisation Good Clinical Practice guidelines,
252 regulations of the US Food and Drug Administration (FDA), and the Declaration of Helsinki.
253 The study protocol was submitted to Institutional Review Boards (IRBs) in accordance with
254 FDA and local regulatory requirements before the start of the study. The following IRBs gave
255 permission for this study to be performed: NorthShore University Health System Institutional
256 Review Board; University of Rochester, Research Subjects Review Board; and Western IRB.

257 **Results**

258 **Participants and summary of testing results**

259 Subjects from 10 geographically diverse healthcare facilities were enrolled in the study. The
260 summary of testing results can be seen in **Supplemental Table A**. A total of 2,209 SARS-
261 CoV-2 results from prospective samples (both nasal and nasopharyngeal swabs) were valid
262 for inclusion in downstream analyses.

263 **Population and baseline characteristics**

264 Baseline demographic data for study participants were available for the prospectively
265 collected samples; details on the study participants are presented in **Table 1**. Of these
266 subjects, 506 were male (47.8%) and 553 were female (52.2%). The median age was 35
267 years (range 0–86).

268 Patient characteristics are present in **Supplemental Table B**. In total, 60.4% of subjects in
269 the prospective population had signs and symptoms of respiratory infection, with days from
270 onset of first symptom ranging from 1 to 365 days. The remaining 39.6% of subjects were
271 asymptomatic but were clinically suspected of SARS-CoV-2 infection by their healthcare
272 provider due to recent exposure or other reason. The nasal swab samples were evenly
273 distributed between HCW-collected and self-collected.

274 **Medical history**

275 The medical history relating to vaccination status is presented in **Table 2**. Most participants
276 received a COVID-19 vaccine (68.7%), with Pfizer as the most common vaccine for both first
277 and second doses (69.5% and 72.2%, respectively).

278 **SARS-CoV-2**

279 Determination of the composite comparator status for SARS-CoV-2

280 In symptomatic study participants, the composite comparator method was SARS-CoV-2
281 positive for 134 nasal and 131 nasopharyngeal swab samples (**Supplemental Table C**).

282 In asymptomatic study participants, the composite comparator method was SARS-CoV-2
283 positive for 39 nasal and 39 nasopharyngeal swab samples (**Supplemental Table C**).

284 Performance

285 The total number of samples that were positive, negative, or invalid, and how these align
286 with the composite comparator status, can be seen in **Figure 1**. The diagnostic performance
287 (total number of positive and negative results) for SARS-CoV-2 can be seen in **Table 3**.

288 Agreement between the composite comparator and the Cobas Liat SARS-CoV-2 & Influenza
289 A/B test for detection of SARS-CoV-2 in nasal swabs (total, prospective and retrospective,
290 self-collected or HCW-collected), nasopharyngeal swabs (total, prospective and
291 retrospective), in samples from vaccinated and unvaccinated participants, and in
292 symptomatic and asymptomatic participants can be seen in **Supplemental Table D**. For
293 nasal swab samples, the total OPA, PPA, and NPA was 98.8% (95% CI: 97.9, 99.3), 97.1%
294 (95% CI: 93.3, 98.7), and 99.1% (95% CI: 98.2, 99.5), respectively. Of note, the OPA for
295 HCW-collected nasal swab samples was 98.4% (95% CI: 97.0, 99.2) and 99.1% (95% CI:
296 98.0, 99.6) for self-collected nasal swab samples. The total OPA, PPA, and NPA for
297 nasopharyngeal swab samples was 99.0% (95% CI: 98.2, 99.4), 96.4% (95% CI: 92.4,
298 98.4), and 99.4% (95% CI: 98.7, 99.8), respectively.

299 Using all paired results for nasal and nasopharyngeal swab samples by subject, the swab
300 type did not make a difference in the reported result (McNemar's mid-p test, $P=0.771$).

301 Cycle threshold (Ct) value distributions

302 The range of Ct values in nasal and nasopharyngeal swab samples can be seen in **Figure 2**.
303 Self-collected nasal swabs showed the highest average viral load followed by
304 nasopharyngeal swabs, then HCW-collected nasal swabs.

305 The range of Ct values in subject-paired nasal and nasopharyngeal swab samples can be
306 seen in **Figure 3**. The Deming regression analysis showed that the two sample types were
307 highly correlated (**Figure 3A**; $r = 0.83$). Exploration of the collection method showed that
308 HCW-collected nasal swabs had greater concordance between the paired samples (**Figure**
309 **3B**; $r = 0.91$) than the self-collected nasal swabs ($r = 0.77$; **Figure 3C**).

310 Discordance

311 Fourteen nasal and 11 nasopharyngeal swab samples showed discordant results between
312 the Cobas Liat SARS-CoV-2 & Influenza A/B test and the centralized testing methods
313 (**Supplemental Table E**); 10 were positive only on the Cobas Liat SARS-CoV-2 & Influenza
314 A/B test.

315 **Influenza A**

316 Performance

317 The agreement between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the Cobas
318 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza A in nasopharyngeal
319 swabs (total, prospective and retrospective) and nasal swabs (total, prospective and
320 retrospective, HCW-collected or self-collected) can be seen in **Supplemental Table**
321 **FError! Reference source not found.** The OPA ranged from 98.9% to 100.0%.

322 Discordance

323 Two nasal and five nasopharyngeal swab samples showed discordant results between the
324 Cobas Liat SARS-CoV-2 & Influenza A/B test and the Cobas 6800/8800 SARS-CoV-2 &
325 Influenza A/B test for detection of influenza A (**Supplemental Table G**), four of which
326 were positive only on the Cobas Liat SARS-CoV-2 & Influenza A/B test.

327 **Influenza B**

328 Performance

329 The agreement between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the Cobas
330 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza B in nasopharyngeal
331 swabs (total, prospective and retrospective) and nasal swabs (total, prospective and
332 retrospective, self-collected nasal or HCW-collected) can be seen in **Supplemental Table**
333 **H**. The OPA for all comparisons was 100.0%.

334 Discordance

335 No discordant results between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the
336 Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza B were
337 recorded.

338 **Evaluation of the ease of use for the Cobas Liat system**

339 Twenty-seven operators with experience of testing samples on the Cobas Liat completed the
340 questionnaire. The operators' average scores indicating their agreement with the statements
341 in the questionnaire are shown in **Supplemental Table I**. The overall score was 4.5 out of
342 5 for the operators' answers to all eight statements, indicating that the operators agreed
343 that the Cobas Liat system was easy to use.

344 **Inclusivity analysis**

345 The Cobas Liat SARS-CoV-2 & Influenza A/B test targets the nucleocapsid (N) and ORF1a/b
346 regions of the SARS-CoV-2 genome.(34) *In silico* analysis showed that 99.98% of NCBI and
347 99.99% of GISAID sequences for SARS-CoV-2 had no changes in the primer/probe binding
348 sites of both target regions simultaneously. All sequences were predicted to be detected by
349 at least one of the two sites.

350 **Discussion**

351 In this study, we evaluated the performance of the POC RT-PCR Cobas Liat SARS-CoV-2 &
352 Influenza A/B test against up to three centralized assays, stratified by various parameters.
353 The high performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test in comparison
354 with centralized testing methods utilizing nasopharyngeal or nasal samples has previously
355 been reported(37-41), but this study is the first to report the performance of the Cobas Liat
356 SARS-CoV-2 & Influenza A/B test across variables such as collection method (self/HCW,
357 retrospective/prospective), vaccination status, symptom status, and ease of use. Using the
358 comparator result to establish the status of infection, we found high agreement between the
359 POC RT-PCR test and the centralized testing assays for all three analytes across all variables.

360 Previously, a meta-analysis of nucleic acid amplification testing reported that the sensitivity
361 for detection of SARS-CoV-2 in nasal samples may be less than nasopharyngeal
362 samples(42), whilst a study specifically assessing the Cobas Liat SARS-CoV-2 & Influenza
363 A/B test reported similar differences in SARS-CoV-2 detection by sample type(37). However,
364 we saw no evidence of a sample-type difference in sensitivity, with SARS-CoV-2 positivity
365 identified in both nasal and nasopharyngeal swab samples to a similar extent (Cobas Liat
366 SARS-CoV-2 & Influenza A/B test positivity rate approximately 15%; the difference in
367 sensitivity [nasal minus nasopharyngeal] was +0.9%).

368 A small study from Denmark found almost equivalent sensitivity for detection of SARS-CoV-2
369 using self- and HCW-collected samples (84.2% vs 89.5%, respectively), and that patients
370 preferred self-collection(43). In our study, whether nasal samples were collected by HCWs or
371 by the patients themselves had little impact on the agreement values between the POC RT-
372 PCR test and the comparators. Indeed, in all comparisons the agreement for self-collected
373 samples was actually higher than for HCW-collected samples. For SARS-CoV-2, Ct values of
374 paired nasal and nasopharyngeal swab samples as measured by the POC RT-PCR test were
375 highly correlated, and Ct values were on average lower in nasal swab samples (i.e., higher
376 viral RNA titer) compared with nasopharyngeal swab samples, with self-collected nasal

377 swabs exhibiting the lowest Ct values. Collectively, this indicates that the high performance
378 level of the POC RT-PCR test is maintained across collection methods, and that patients are
379 able to self-sample effectively, and are willing to do so.

380 We identified a small number of discrepant samples for the SARS-CoV-2 analyte in both
381 nasal and nasopharyngeal swab samples, consistent with other studies(37, 38), most of
382 which were false positives. The majority of the false positives were in the high Ct/low viral
383 titer range (Cobas Liat SARS-CoV-2 & Influenza A/B test Ct values: lowest 28.2, median
384 35.2, highest 37.1) and thus close to or at the lower limit of detection of Ct 35.2 (USA-
385 WA1/2020 strain) for the Cobas Liat SARS-CoV-2 & Influenza A/B test(34). Of the false
386 negatives detected by the Cobas Liat SARS-CoV-2 & Influenza A/B test, all except one
387 sample were in the high Ct range. Indeed, after exploratory re-testing of false-negative
388 nasopharyngeal samples, two were found to be positive (re-tested Ct values were 34.8 and
389 35.4). Generally, low viral burden can be a cause of discrepant results(44), and a small
390 external quality assessment (reproducibility) study reported that the performance of the
391 Cobas Liat SARS-CoV-2 & Influenza A/B test is highest at low Ct values(45).

392 US legislation categorizes tests for complexity (moderate or high) using seven criteria, such
393 as the need for training and experience, and assigns scores within each criterion(45). Test
394 systems can be assigned as 'waived complexity' under certain conditions, and these tests
395 require no formal operator training or competency(45). In addition to CLIA-certified
396 laboratories, the Cobas Liat SARS-CoV-2 & Influenza A/B test is authorized for use in patient
397 care settings that are CLIA waived(34). In conjunction with the fast turnaround offered by
398 the Cobas Liat system and demonstrated in studies of the Cobas Liat SARS-CoV-2 &
399 Influenza A/B test in real-world settings (40, 46) or studies evaluating workflow or
400 processing time(41, 47), our study confirms that the Cobas Liat SARS-CoV-2 & Influenza A/B
401 test is easy to use in CLIA-waived settings, and offers results in a timeframe conducive for
402 rapid patient management.

403 The strength of our multicenter study lies in the comprehensive nature of the variables
404 assessed, encompassing a wide variety of patient characteristics likely to be encountered in
405 healthcare settings. The study included a prospectively enrolled cohort of patients seeking
406 care, which is representative of the intended-use population of the Cobas Liat SARS-CoV-2 &
407 Influenza A/B test. Our study has some limitations. Firstly, we did not ascertain the SARS-
408 CoV-2 variants present in the samples. Whilst the emergence of SARS-CoV-2 variants has
409 the ability to affect the diagnostic performance of the test, previous studies have indicated
410 that the Cobas Liat SARS-CoV-2 & Influenza A/B test detects both wild-type and variants of
411 concern, such as Alpha (B.1.1.7) or Omicron (B.1.1.529)(39, 47). Bioinformatic analysis to
412 assess inclusivity showed that the Cobas Liat SARS-CoV-2 & Influenza A/B test is predicted
413 to bind all sequences available in the NCBI and GISAID databases as of July 2024. The dual
414 target assay design helps to ensure that the assay is robust and safeguards against the
415 emergence of variants that have the potential to affect assay performance and evade
416 detection.

417 **Conclusion**

418 A POC RT-PCR test combining both measurement of SARS-CoV-2 and influenza subtypes
419 with performance equivalent to routine centralized testing would provide a critical tool to
420 improve the diagnosis and management of COVID-19 and influenza. We found that the
421 performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test was comparable to
422 centralized testing methods. With the ease of use and equivalent performance, it highlights
423 the question as to whether centralized testing should be considered as the gold standard. A
424 study of the Cobas Liat Influenza A/B test (a Liat RT-PCR test that detects only the influenza
425 analyte) in the emergency department found that POC testing for influenza was useful in
426 improving several metrics, including the indication for treatment with neuraminidase in
427 positive cases(48). It is relevant to note that SARS-CoV-2 and influenza coinfection can
428 increase the risk of severe outcomes compared with those infected with SARS-CoV-2 alone,

429 particularly for those coinfecting with influenza A.(49) Our study highlights the benefits of
430 molecular multiplex POCT to help improve timely differentiation of respiratory diseases that
431 share similar symptoms and support efforts to improve patient management.

432 **Funding**

433 This study was funded by Roche Molecular Systems, Inc (Pleasanton, California, USA).

434 **Disclosures**

435 EMR, RB, HC, LM, and CN are employees of Roche Molecular Systems, Inc. EMR participates
436 in Roche Connect and is a shareholder.

437 Assay disclaimers

438 The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system
439 (herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test) was originally
440 approved under Emergency Use Authorization EUA201779 and has since been cleared and
441 Clinical Laboratory Improvement Amendments (CLIA) waived under 223591/CW220014,
442 respectively, in the US and is CE-IVD marked in the European Union. Sample collection in
443 the patient's home is not approved in the US or European Union.

444 The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800
445 systems (herein referred to as the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test) is
446 authorized only for use under Emergency Use Authorization (EUA) in the US, and is CE-IVD
447 marked in the European Union. The assay is not approved for use in asymptomatic patients
448 in the US or European Union. The assay is not approved for use as a point-of-care (POC)
449 test/near-patient test (NPT) in the US/European Union. Sample collection in the patient's
450 home is not approved in the US or European Union.

451 The Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein
452 referred to as the Cobas 6800/8800 SARS-CoV-2 test) is authorized only for use under EUA

453 in the US, and is CE-IVD marked in the European Union. The assay is not approved for use
454 as a POC test/NPT in the US/European Union. Sample collection in the patient's home is not
455 approved in the US or European Union.

456 Hologic Aptima SARS-CoV-2 assay is an FDA EUA assay.(30)

457 **Data availability**

458 The datasets generated during and/or analyzed during the current study are not publicly
459 available due to patient confidentiality. Any access requests from qualified researchers
460 should be submitted directly to the Ethical Committee of each participating study site.

461 **Acknowledgments**

462 Medical writing support was provided by Corrinne Segal of Elements Communications Ltd
463 (London, UK) and was funded by Roche Molecular Systems, Inc.


464 COBAS and LIAT are trademarks of Roche. All other product names and trademarks are the
465 property of their respective owners.

466 We would like to thank Saima Shams and Vaishali Mody for their contributions to the
467 development of the Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the
468 Cobas Liat system (herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test),
469 and Jingtao Sun for his bioinformatics expertise.

470 **Figures**

471

472 Figure 1: Detection of SARS-CoV-2 using the Cobas[®] Liat[®] SARS-CoV-2 & Influenza A/B test and the composite comparator (prospective and
 473 retrospective, symptomatic and asymptomatic subjects)^a



474

475 Abbreviations: CC, composite comparator; POC RT-PCR, point-of-care RT-PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

476 ^aThe composite comparator comprises the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test, Cobas 6800/8800 SARS-CoV-2 test, and

477 Hologic[®] Aptima[®] SARS-CoV-2 Assay; the POC RT-PCR test is the Cobas Liat SARS-CoV-2 & Influenza A/B test.


478 The Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is herein referred to as the Cobas Liat SARS-CoV-2 &

479 Influenza A/B test. The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems is herein referred to as

480 the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test. Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems is herein

481 referred to as the Cobas 6800/8800 SARS-CoV-2 test.

482 Figure 2: C_t values for the SARS-CoV-2 analyte from the Cobas[®] Liat[®] SARS-CoV-2 & Influenza A/B test in nasal and nasopharyngeal swab
483 samples^a



484

485 Abbreviations: Ct, cycle threshold; HCW, healthcare worker-collected; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

486 ^aFalse positives are represented by black circles. Cross represents mean Ct values. Nasal (total): n=179, mean Ct 23.1, median Ct 21.9,

487 minimum Ct 11.0, maximum Ct 36.8; HCW-collected nasal: n=87, mean Ct 23.9, median Ct 23.7, minimum Ct 12.3, maximum Ct 36.8; self-

488 collected nasal: n=92, mean Ct 22.4, median Ct 21.1, minimum Ct 11.0, maximum Ct 36.1; nasopharyngeal: n=177, mean Ct 23.4, median Ct
489 22.8, minimum Ct 10.6, maximum Ct 37.1.

490 False positives are indicated by black circles. The Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is
491 herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test. Horizontal solid line represents median values. Upper and lower
492 boundaries of box plot represent 75th and 25th percentile.

493


495 Figure 3: Deming regression for the SARS-CoV-2 analyte from the Cobas[®] Liat[®] SARS-CoV-2

496 & Influenza A/B test in subject-paired nasal and nasopharyngeal swab samples^a

497 A: Nasal (total)

498 B: HCW-collected nasal swab

499 C: Self-collected nasal swab



500

501

502 Abbreviations: Ct, cycle threshold; FP, false positive; HCW, healthcare worker-collected; NPS,

503 nasopharyngeal swab; NS, nasal; NS FP, nasal false positive; SARS-CoV-2, severe acute

504 respiratory syndrome coronavirus 2.

505 ^aThe Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is

506 herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test. Prospective

507 symptomatic = open circle; prospective exposed = triangle. Dashed line represents perfect

508 correlation. Solid line represents Deming regression. Red data points represent HCW-

509 collected nasal swabs. Blue data points represent self-collected nasal swabs.

510

511

512 **Tables**

513 Table 1: Demographics (prospective symptomatic and asymptomatic subjects)

Characteristics	Prospective population
Total	
N	1,059
Age (years)	
Mean	34.2
Standard deviation	19.88
Median	35.0
Range (minimum–maximum) ^a	0.0–86.0
Age group (years), n (%)	
≤ 18	287 (27.1)
19–39	319 (30.1)
40–64	391 (36.9)
≥ 65	62 (5.9)
Sex at birth, n (%)	
Male	506 (47.8)
Female	553 (52.2)
Ethnicity, n (%)	
Hispanic/Latino	212 (20.0)
Not Hispanic/not Latino	589 (55.6)
Not reported ^b	236 (22.3)
Unknown ^c	22 (2.1)
Race, n (%)	
American Indian/Alaskan Native	3 (0.3)
Asian	37 (3.5)
Black/African American	175 (16.5)
Native Hawaiian/Pacific Islander	6 (0.6)
White	520 (49.1)
Other	56 (5.3)
Not reported ^b	262 (24.7)

514

515 ^aAll subjects <1 year old are counted as age 0.

516 ^bA clinical site that was a mobile drive-through site was not able to collect race/ethnicity
517 identification from subjects.

518 ^cUnknown category indicates subjects for whom the corresponding information is not
519 available.

520

521

522 Table 2: Subject medical history (prospective symptomatic and asymptomatic subjects)

523

Characteristics	Population statistics
Total	
N	1,059
Subject received the influenza vaccine within the last 6 weeks, n (%)	
Yes	14 (1.3)
No	1,045 (98.7)
Unknown	0 (0.0)
Influenza vaccine route of administration, n (%)^a	
Intramuscular	14 (100.0)
Intranasal	0 (0.0)
Unknown	0 (0.0)
Subject received a COVID-19 vaccine, n (%)	
Yes	728 (68.7)
No	303 (28.6)
Unknown	28 (2.6)
Type of COVID-19 vaccine received for first dose, n (%)^b	
Pfizer	506 (69.5)
Moderna	185 (25.4)
Johnson & Johnson (J & J)	30 (4.1)
Other	3 (0.4)
Unknown	4 (0.5)
Type of COVID-19 vaccine received for second dose, n (%)^b	
Pfizer	488 (72.2)
Moderna	182 (26.9)
Other	3 (0.4)
Unknown	3 (0.4)
Type of COVID-19 vaccine received first booster, n (%)^{b,c}	
Pfizer	217 (64.0)
Moderna	115 (33.9)

Characteristics	Population statistics
Johnson & Johnson (J & J)	5 (1.5)
Other	1 (0.3)
Unknown	1 (0.3)

524

525 Abbreviations: COVID-19, coronavirus disease 2019

526 ^aPercentages calculated based on number of subjects who received the influenza vaccine

527 within the last 6 weeks prior to enrollment and sample collection.

528 ^bPercentages calculated based on number of subjects who received COVID-19 vaccine or

529 first booster.

530 ^cThere were six subjects that reported receiving a second booster.

531

532

533 Table 3: Results for the detection of SARS-CoV-2 using the composite comparator compared with the Cobas® Liat® SARS-CoV-2 & Influenza

534 A/B test^a

	Composite comparator (+)	Composite comparator (-)	Total	PPA % (95% CI)	NPA % (95% CI)
Nasal					
Cobas Liat SARS-CoV-2 & Influenza A/B test (+)	165	9	174	97.1 (93.3, 98.7)	99.1 (98.2, 99.5)
Cobas Liat SARS-CoV-2 & Influenza A/B test (-)	5	961	966		
Total	170	970	1,140		
Nasopharyngeal					
Cobas Liat SARS-CoV-2 & Influenza A/B test (+)	162	5	167	96.4 (92.4, 98.4)	99.4 (98.7, 99.8)
Cobas Liat SARS-CoV-2 & Influenza A/B test (-)	6	896	902		
Total	168	901	1,069		

535

536 Abbreviations: CI, Score confidence interval; NPA, negative percent agreement; PPA, positive percent agreement; SARS-CoV-2, severe acute
 537 respiratory syndrome coronavirus 2.

538 ^aThe Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is herein referred to as the Cobas Liat SARS-CoV-2
 539 & Influenza A/B test.

540 **References**

- 541 1. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, Macdonald
542 B, Dattani S, Beltekian D, Ortiz-Ospina E, Roser M. 2020. Coronavirus
543 pandemic (COVID-19). <https://ourworldindata.org/coronavirus>. Accessed Mar
544 06, 2024.
- 545 2. Ahmad FB, Cisewski JA, Xu J, Anderson RN. 2023. COVID-19 Mortality Update
546 - United States, 2022. *MMWR Morb Mortal Wkly Rep* 72:493–496.
- 547 3. Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. 2023. Clinical course
548 and management of COVID-19 in the era of widespread population immunity.
549 *Nat Rev Microbiol* 22:75–88.
- 550 4. Antinori A, Bausch-Jurken M. 2023. The burden of COVID-19 in the
551 immunocompromised patient: implications for vaccination and needs for the
552 future. *J Infect Dis* 228:S4–S12.
- 553 5. Wiemken TL, Khan F, Puzniak L, Yang W, Simmering J, Polgreen P, Nguyen JL,
554 Jodar L, McLaughlin JM. 2023. Seasonal trends in COVID-19 cases,
555 hospitalizations, and mortality in the United States and Europe. *Sci Rep*
556 13:3886.
- 557 6. Moriyama M, Hugentobler WJ, Iwasaki A. 2020. Seasonality of Respiratory
558 Viral Infections. *Annu Rev Virol* 7:83–101.
- 559 7. World Health Organization. 2024. Coronavirus disease (COVID-19):
560 similarities and differences between COVID-19 and influenza.
561 [https://www.who.int/news-room/questions-and-answers/item/coronavirus-](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-similarities-and-differences-with-influenza)
562 [disease-covid-19-similarities-and-differences-with-influenza](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-similarities-and-differences-with-influenza). Accessed Aug 05,
563 2024.

- 564 8. Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, Dos Santos
565 Ferreira CE, Tateda K, Van Der Pol B. 2022. Choice of SARS-CoV-2 diagnostic
566 test: challenges and key considerations for the future. *Crit Rev Clin Lab Sci*
567 59:445–459.
- 568 9. Hayden MK, Hanson KE, Englund JA, Lee MJ, Loeb M, Lee F, Morgan DJ, Patel
569 R, El Mikati IK, Iqneibi S, Alabed F, Amarin JZ, Mansour R, Patel P, Falck-Ytter
570 Y, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. 2023. The
571 Infectious Diseases Society of America guidelines on the diagnosis of
572 coronavirus disease 2019 (COVID-19): molecular diagnostic testing. *Clin*
573 *Infect Dis* doi:10.1093/cid/ciad646.
- 574 10. Katzenschlager S, Brümmer LE, Schmitz S, Tolle H, Manten K, Gaeddert M,
575 Erdmann C, Lindner A, Tobian F, Grilli M, Pollock NR, Macé A, Erkosar B,
576 Carmona S, Ongarello S, Johnson CC, Sacks JA, Denkinger CM, Yerlikaya S.
577 2023. Comparing SARS-CoV-2 antigen-detection rapid diagnostic tests for
578 COVID-19 self-testing/self-sampling with molecular and professional-use
579 tests: a systematic review and meta-analysis. *Sci Rep* 13:21913.
- 580 11. Tolan NV, Horowitz GL. 2022. Clinical diagnostic point-of-care molecular
581 assays for SARS-CoV-2. *Clin Lab Med* 42:223–236.
- 582 12. Shirley JD, Bennett SA, Binnicker MJ. 2023. Current regulatory landscape for
583 viral point-of-care testing in the United States. *J Clin Virol* 164:105492.
- 584 13. Fragkou PC, Moschopoulos CD, Dimopoulou D, Ong DSY, Dimopoulou K,
585 Nelson PP, Schweitzer VA, Janocha H, Karofylakis E, Papathanasiou KA,
586 Tsiordras S, De Angelis G, Thölken C, Sanguinetti M, Chung HR, Skevaki C.
587 2023. Performance of point-of care molecular and antigen-based tests for

- 588 SARS-CoV-2: a living systematic review and meta-analysis. *Clin Microbiol*
589 *Infect* 29:291–301.
- 590 14. Bigio J, MacLean EL, Das R, Sulis G, Kohli M, Berhane S, Dinnes J, Deeks JJ,
591 Brümmer LE, Denkinger CM, Pai M. 2023. Accuracy of package inserts of
592 SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus
593 systematic review data. *Lancet Microbe* 4:e875–e882.
- 594 15. Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, Omer SB, Abbas
595 Q, Ali A, Amu A, Azziz-Baumgartner E, Bassat Q, Abdullah Brooks W, Chaves
596 SS, Chung A, Cohen C, Echavarria M, Fasce RA, Gentile A, Gordon A, Groome
597 M, Heikkinen T, Hirve S, Jara JH, Katz MA, Khuri-Bulos N, Krishnan A, de Leon
598 O, Lucero MG, McCracken JP, Mira-Iglesias A, Moïsi JC, Munywoki PK,
599 Ourohiré M, Polack FP, Rahi M, Rasmussen ZA, Rath BA, Saha SK, Simões EA,
600 Sotomayor V, Thamthitiwat S, Treurnicht FK, Wamukoya M, Yoshida LM, Zar
601 HJ, Campbell H, Nair H. 2020. Global burden of respiratory infections
602 associated with seasonal influenza in children under 5 years in 2018: a
603 systematic review and modelling study. *Lancet Glob Health* 8:e497–e510.
- 604 16. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, Simonsen
605 L, Viboud C. 2019. Global mortality associated with seasonal influenza
606 epidemics: new burden estimates and predictors from the GLaMOR Project. *J*
607 *Glob Health* 9:020421.
- 608 17. GBD 2017 Influenza Collaborators. 2019. Mortality, morbidity, and
609 hospitalisations due to influenza lower respiratory tract infections, 2017: an
610 analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med*
611 7:69–89.

- 612 18. Maleki F, Welch V, Lopez SMC, Cane A, Langer J, Enstone A, Markus K, Wright
613 O, Hewitt N, Whittle I. 2023. Understanding the global burden of influenza in
614 adults aged 18-64 years: a systematic literature review from 2012 to 2022.
615 *Adv Ther* 40:4166–4188.
- 616 19. Gibson J, Schechter-Perkins EM, Mitchell P, Mace S, Tian Y, Williams K, Luo R,
617 Yen-Lieberman B. 2017. Multi-center evaluation of the Cobas® Liat®
618 Influenza A/B & RSV assay for rapid point of care diagnosis. *J Clin Virol* 95:5–
619 9.
- 620 20. Young S, Phillips J, Griego-Fullbright C, Wagner A, Jim P, Chaudhuri S, Tang S,
621 Sickler J. 2020. Molecular point-of-care testing for influenza A/B and
622 respiratory syncytial virus: comparison of workflow parameters for the ID Now
623 and Cobas Liat systems. *J Clin Pathol* 73:328–334.
- 624 21. Azar MM, Landry ML. 2018. Detection of influenza A and B viruses and
625 respiratory syncytial virus by use of Clinical Laboratory Improvement
626 Amendments of 1988 (CLIA)-waived point-of-care assays: a paradigm shift to
627 molecular tests. *J Clin Microbiol* 56:e00367-18.
- 628 22. Melchers WJG, Kuijpers J, Sickler JJ, Rahamat-Langendoen J. 2017. Lab-in-a-
629 tube: real-time molecular point-of-care diagnostics for influenza A and B using
630 the Cobas® Liat® system. *J Med Virol* 89:1382–1386.
- 631 23. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein
632 S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL,
633 McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. 2019. Clinical practice
634 guidelines by the Infectious Diseases Society of America: 2018 update on

- 635 diagnosis, treatment, chemoprophylaxis, and institutional outbreak
636 management of seasonal influenza. *Clin Infect Dis* 68:895–902.
- 637 24. Berry L, Lansbury L, Gale L, Carroll AM, Lim WS. 2020. Point of care testing of
638 Influenza A/B and RSV in an adult respiratory assessment unit is associated
639 with improvement in isolation practices and reduction in hospital length of
640 stay. *J Med Microbiol* 69:697–704.
- 641 25. Rahamat-Langendoen J, Groenewoud H, Kuijpers J, Melchers WJG, van der
642 Wilt GJ. 2019. Impact of molecular point-of-care testing on clinical
643 management and in-hospital costs of patients suspected of influenza or RSV
644 infection: a modeling study. *J Med Virol* 91:1408–1414.
- 645 26. Mikamo H, Koizumi Y, Yamagishi Y, Asai N, Miyazono Y, Shinbo T, Horie M,
646 Togashi K, Robbins EM, Hirotsu N. 2022. Comparing the Cobas Influenza A/B
647 Nucleic acid test for use on the Cobas Liat System (Liat) with rapid antigen
648 tests for clinical management of Japanese patients at the point of care. *PLoS*
649 *One* 17:e0276099.
- 650 27. Roche Molecular Systems Inc. 2021. Cobas® Liat® System User Guide.
- 651 28. Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-
652 2. Qualitative assay for use on the Cobas® 6800/8800 Systems. P/N:
653 09179917001-07EN.
- 654 29. Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-
655 2 & Influenza A/B. Qualitative assay for use on the Cobas® 6800/8800
656 Systems. P/N: 09233474190.

- 657 30. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. 2020.
658 Comparison of the analytical sensitivity of seven commonly used commercial
659 SARS-CoV-2 automated molecular assays. *J Clin Virol* 130:104578.
- 660 31. Copan Diagnostics Inc. 2020. Instructions for use. FLOQSwabs. HPC217
661 Rev.00 Date 2020.10. [https://www.copanusa.com/wp-](https://www.copanusa.com/wp-content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf)
662 [content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf](https://www.copanusa.com/wp-content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf).
663 Accessed Aug 5, 2024.
- 664 32. Centers for Disease Control and Prevention. 2023. 2021-2022 flu season
665 summary. [https://www.cdc.gov/flu/season/faq-flu-season-2021-](https://www.cdc.gov/flu/season/faq-flu-season-2021-2022.htm#print)
666 [2022.htm#print](https://www.cdc.gov/flu/season/faq-flu-season-2021-2022.htm#print). Accessed Aug 05, 2024.
- 667 33. Dzung A, Cheng PF, Stoffel C, Tastanova A, Turko P, Levesque MP, Bosshard
668 PP. 2021. Prolonged unfrozen storage and repeated freeze-thawing of SARS-
669 CoV-2 patient samples have minor effects on SARS-CoV-2 detectability by RT-
670 PCR. *J Mol Diagn* 23:691–697.
- 671 34. Roche Molecular Systems Inc. 2020. Instructions for use. Cobas® SARS-CoV-
672 2 & Influenza A/B. Nucleic acid test for use on the Cobas® Liat® System.
673 P/N: 09211101190.
- 674 35. Hologic. 2020. Instructions for use. Aptima® SARS-CoV-2 Assay (Panther®
675 System).
- 676 36. Wilson E. 1927. Probable inference, the law of succession, and statistical
677 inference. *J Am Stat Assoc* 22:209–212.
- 678 37. Akashi Y, Horie M, Kiyotaki J, Takeuchi Y, Togashi K, Adachi Y, Ueda A, Notake
679 S, Nakamura K, Terada N, Kurihara Y, Kiyasu Y, Suzuki H. 2022. Clinical

- 680 performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in nasal
681 samples. *Mol Diagn Ther* 26:323–331.
- 682 38. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF,
683 Jin R, Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical
684 performance of the point-of-care Cobas Liat for detection of SARS-CoV-2 in 20
685 minutes: a multicenter study. *J Clin Microbiol* 59:e02811-20.
- 686 39. Park K, Sung H, Kim MN. 2023. Evaluation of the cobas Liat detection test for
687 SARS-CoV-2 and influenza viruses following the emergence of the SARS-CoV-2
688 Omicron variant. *Diagn Microbiol Infect Dis* 105:115891.
- 689 40. Er TK, Chou YC, Chen SY, Huang JW. 2021. Rapid cobas Liat SARS-CoV-2
690 assay in comparison with the laboratory-developed real-time RT-PCR test. *Clin*
691 *Lab* 67.
- 692 41. Matic N, Lawson T, Ritchie G, Lowe CF, Romney MG. 2024. Testing the limits
693 of multiplex respiratory virus assays for SARS-CoV-2 at high cycle threshold
694 values: Comparative performance of Cobas 6800/8800 SARS-CoV-2 &
695 Influenza A/B, Xpert Xpress SARS-CoV-2/Flu/RSV, and Cobas Liat SARS-CoV-2
696 & Influenza A/B. *J Assoc Med Microbiol Infect Dis Can* 8:328-335.
- 697 42. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021.
698 Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2
699 molecular detection: a systematic review and meta-analysis. *J Clin Microbiol*
700 59:e02881-20.
- 701 43. Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB,
702 Thudium RF, Kirkby NS, Raaschou-Pedersen DET, Bundgaard JS, Iversen K,
703 Bundgaard H, Todsén T. 2020. Self-collected versus healthcare worker-

- 704 collected swabs in the diagnosis of severe acute respiratory syndrome
705 coronavirus 2. *Diagnostics* 10:678.
- 706 44. Craney AR, Velu PD, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, La Spina
707 M, Lei B, Chen A, Alston T, Rozman A, Loda M, Rennert H, Cushing M,
708 Westblade LF. 2020. Comparison of two high-throughput reverse
709 transcription-PCR systems for the detection of severe acute respiratory
710 syndrome coronavirus 2. *J Clin Microbiol* 58:e00890-20.
- 711 45. Buchta C, Zeichhardt H, Badrick T, Coucke W, Wojtalewicz N, Griesmacher A,
712 Aberle SW, Schellenberg I, Jacobs E, Nordin G, Schweiger C, Schwenoha K,
713 Luppä PB, Gassner UM, Wagner T, Kammel M. 2023. Classification of "near-
714 patient" and "point-of-care" SARS-CoV-2 nucleic acid amplification test
715 systems and a first approach to evaluate their analytical independence of
716 operator activities. *J Clin Virol* 165:105521.
- 717 46. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. 2023. A study to assess
718 the impact of the Cobas point-of-care RT-PCR assay (SARS-CoV-2 and
719 Influenza A/B) on patient clinical management in the emergency department
720 of the University of California at Davis Medical Center. *J Clin Virol* 168:105597.
- 721 47. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW, Li SY, Hsieh SS, Liu
722 MT, Yang JR, Tang SH, Perng CL, Chang FY, Shang HS. 2021. Clinical
723 comparison of three sample-to-answer systems for detecting SARS-CoV-2 in
724 B.1.1.7 lineage emergence. *Infect Drug Resist* 14:3255–3261.
- 725 48. Perlitz B, Slagman A, Hitzek J, Riedlinger D, Möckel M. 2021. Point-of-care
726 testing for influenza in a university emergency department: a prospective
727 study. *Influenza Other Respir Viruses* 15:608–617.

- 728 49. Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. 2023. Prevalence and associated
729 outcomes of coinfection between SARS-CoV-2 and influenza: a systematic
730 review and meta-analysis. *Int J Infect Dis* 136:29–36.
731